Litcius/Paper detail

Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin

Efe Eworuke, Laura Hou, Rongmei Zhang, Hui‐Lee Wong, Peter Waldron, Abby Anderson, Audrey Gassman, David Moeny, Ting‐Ying Huang

2021Drug Safety19 citationsDOI

Topics & Concepts

MedicineApixabanRivaroxabanDabigatranWarfarinHazard ratioAtrial fibrillationRetrospective cohort studyInternal medicineAnesthesiaConfidence intervalUterine Myomas and TreatmentsMaternal and fetal healthcareBlood Coagulation and Thrombosis Mechanisms
Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin | Litcius